BioSpace News Archive

Orchard Therapeutics, a leading commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies, today announced two additions to its executive leadership team.

Pond Technologies Holdings Inc. (TSX.V: POND) has, subject to regulatory approval, retained Venture Liquidity Providers Inc. (VLP) to initiate its market-making service to provide assistance in maintaining an orderly trading market for the common shares of the company.

Sandra Martinez and Jessica Morales, who work for the Life Steps Foundation, are more than direct support professionals to the woman with disabilities they serve. They are Carla’s roommates, and like family to her and her parents. Their dedication to enhancing Carla’s life was most evident after she was diagnosed with stage 4 cancer

GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, today announced the strengthening of its scientific team through the addition of two PhD-level scientists.

ITUS Corporation and its research partner, Moffitt Cancer Center, today announced that a pre-IND meeting with the US FDA has been scheduled on Tuesday, October 16, 2018. The meeting is to discuss numerous aspects of the planned clinical trial of their CAR-T therapy for ovarian cancer.

DarioHealth Corp. announced today that Olivier Jarry, a prominent global life sciences and consumer health executive, has joined the Company as President and Chief Commercial Officer.

NanoViricides, Inc. announced today that it will be presenting at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC.

A 700 Percent Markup Could Result in Patients Being Billed $1,050 for a $150 Medicine

Founded in 1965, the practice is a leading provider of comprehensive musculoskeletal care to patients in the greater Washington, DC market.

Phase Ib/II trial will evaluate safety, pharmacokinetics, pharmacodynamics, efficacy of the immunotherapy combination in PD-1/PD-L1-Refractory Advanced Squamous Cell Cancer of the Head and Neck